(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025, in Las Vegas, Nevada, was host to the IP24: Bladder Cancer: Invasive II Session. Dr. Kazutaka ...

Predicting the Development of BCG-unresponsive Disease Among Patients with High-grade Non-muscle-invasive Bladder Cancer: An International Multicenter Analysis. June 26, 2026 Spatial architecture ...

(UroToday.com) The 2026 ASCO annual meeting featured a radioligand innovation in prostate cancer session and a presentation by Dr. Michael Morris discussing CONVERGE-01 Part 3 assessing Ac-225 ...

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10 th and 13 th, 2023 was host to a plenary session addressing the “right management” ...

(UroToday.com) The 2023 American Urological Association (AUA) annual meeting held in Chicago, IL between April 28 and May 1st, 2023, was host to a plenary session, with Dr. John Wei presenting the ...

(UroToday.com) The 2026 American Urological Association annual meeting featured a plenary session, a behind-the-scenes session on leading Urology clinical trials, and a presentation by Dr. Jason ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in ...

(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang Fendler discussing external validation of new prostate cancer risk groups by PSMA-PET.

(UroToday.com) The 2026 APCCC meeting featured a management of metastatic hormone-sensitive prostate cancer (mHSPC) session and a presentation by Dr. Robert Jones discussing patients who should ...